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Abstract: Rheumatic diseases encompass a diverse group of chronic disorders that commonly affect
musculoskeletal structures. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most
common, leading to considerable functional limitations and irreversible disability when patients
are unsuccessfully treated. Although the specific causes of many rheumatic conditions remain
unknown, it is generally accepted that immune mechanisms and/or uncontrolled inflammatory
responses are involved in their etiology and symptomatology. In this regard, the bidirectional
communication between neuroendocrine and immune system has been demonstrated to provide
a homeostatic network that is involved in several pathological conditions. Adipokines represent
a wide variety of bioactive, immune and inflammatory mediators mainly released by adipocytes
that act as signal molecules in the neuroendocrine-immune interactions. Adipokines can also be
synthesized by synoviocytes, osteoclasts, osteoblasts, chondrocytes and inflammatory cells in the joint
microenvironment, showing potent modulatory properties on different effector cells in OA and RA
pathogenesis. Effects of adiponectin, leptin, resistin and visfatin on local and systemic inflammation
are broadly described. However, more recently, other adipokines, such as progranulin, chemerin,
lipocalin-2, vaspin, omentin-1 and nesfatin, have been recognized to display immunomodulatory
actions in rheumatic diseases. This review highlights the latest relevant findings on the role of the
adipokine network in the pathophysiology of OA and RA.
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1. Introduction
According to the World Health Organization “Musculoskeletal disorders comprise more than
150 diagnoses that affect the locomotor system—that is, muscles, bones, joints and associated tissues
such as tendons and ligaments—and are the second largest contributor to disability worldwide [1].
Musculoskeletal conditions generally comprise disorders that affect joints such as osteoarthritis
(OA) and rheumatoid arthritis (RA). Although both diseases have an inflammatory component, the
underlying pathological mechanisms are different.
OA is the most common joint disease affecting 18% of the population above 60 years of age
although young individuals, especially juvenile athletes, can also suffer from this disorder [2]. It has
been demonstrated that it is triggered mainly by biomechanical stress and joint overload, although
obesity and metabolic disease are also considered key risk factors for its development [3–5]. Cartilage,
subchondral bone, and synovium are the main tissues involved in OA pathogenesis. In recent years,
the important contribution of pro-inflammatory mediators such as cytokines, reactive oxygen species
(ROS), nitric oxide, and matrix degrading enzymes have been reported [6].
RA is a severe autoimmune disorder, characterized by chronic inflammation of diarthrodial joints,
leading to cartilage and bone destruction. RA affects 1% of the population worldwide and is related to
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loss of physical function, quality of life and high prevalence of comorbid conditions [7]. RA develops
in genetically susceptible individuals, under the influence of environmental factors, as well as with
the involvement of epigenetic mechanisms. It is a heterogeneous disorder with diverse pathogenic
mechanisms and variable clinical forms [8,9].
Unraveling the mechanisms that underlie both immune regulation and resolution of inflammation
is crucial for the design of new strategies to treat these two highly prevalent rheumatic disorders.
One of the approaches to understand these mechanisms is the study of the neuro-endocrine-immune
systems balance, which is crucial for the maintenance of homeostasis and the effective adaptation to
stressors [10,11]. This intricate communication and their regulatory mechanisms rely in the presence of
common mediators such as neurotransmitters, cytokines, hormones and their receptors. In this sense,
on the one hand, dysregulation in immune-endocrine integrated circuitries have been involved in the
development of chronic metabolic diseases, comprising obesity, diabetes, and metabolic syndrome [12].
On the other hand, RA has been defined as an example of a disease resulting from abnormal interactions
between these systems [13]. Reversal of abnormal cellular phenotypes in this disease has also been
shown: As an example, synovial fibroblasts (SF) from RA patients (RASF) could be reprogrammed
from a cartilage-degrading phenotype towards a regulatory type by hormones/neurotransmitters [14].
Interestingly, adipose tissue has been shown to be not only involved in the energetic homeostasis
but also to act as an endocrine organ by secreting a diverse array of factors referred as adipocytokines.
Products of adipose tissue include adipokines, cytokines, chemokines and complement factors [15].
Adipokines are bioactive proteins, which have emerged as modulators of inflammatory and immune
response, exerting key roles in rheumatic diseases, both at local and systemic level. Adipose tissue is
not the only source of adipokines. Immune cells, chondrocytes as well as synoviocytes also synthesize
these mediators. In musculoskeletal disorders, autocrine, paracrine and endocrine pathways acting
on target cells and tissues such as bone, cartilage and synovial membrane have been described [16].
Higher levels of adipokines in both serum and synovial fluid from RA patients compared with healthy
controls have been reported [17,18]. Moreover, an inflammatory profile in the infrapatellar fat pad
(IPFP) of OA patients has been described [19]. Overall, increasing evidence postulates that adipokines
play an important role in both immune-mediated rheumatic disease and in degenerative disorders
such as OA. In the next sections, we will disclose the most recent data about the role played by these
mediators in these two rheumatic diseases.
2. Pathophysiology of Osteoarthritis and Rheumatoid Arthritis
2.1. Osteoarthritis
OA is a chronic rheumatic disease, considered one of the leading causes of substantial physical and
psychological disability worldwide. OA is a complex multifactorial disorder [20,21], where mechanical,
genetic, biological, biochemical and metabolic factors are involved. It is characterized by cell stress and
extracellular matrix (ECM) degradation, resulting in an imbalance in joint tissue metabolism [22–24].
Although cartilage degradation is the main event in the pathology, OA affects the whole joint, including
the remodeling of adjacent subchondral bone, osteophyte formation and synovial inflammation, which
might culminate in pain, loss of joint function, and disability in advanced stages [21,24–31].
OA cartilage is characterized by an increase of ECM remodeling, cartilage calcification and
angiogenesis [32,33]. Chondrocytes have receptors for responding to mechanical stress and
inflammatory mediators, many of which are also receptors for ECM components, including
cartilage-degradation products [31,34–36]. Activated chondrocytes acquire a hypertrophic phenotype,
proliferating and increasing the release of inflammatory cytokines and chemokines, stress-induced
intracellular signals, ROS, and matrix-degrading enzymes, including aggrecanases and matrix
metalloproteinases (MMPs). In addition, ECM protein production is decreased. Depletion of aggrecan
and degradation of type II collagen are the main events in cartilage destruction when the process
becomes irreversible [37–40].
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Changes in subchondral bone are related to cartilage remodeling, thus playing an important
role in OA progression by the release of catabolic mediators that promote an abnormal metabolism
in chondrocytes [30,41]. Production of inflammatory and degradative mediators by joint cells also
induces the synovial inflammation. Synovitis is characterized by synovial hyperplasia, with SF and
synovial macrophage proliferation, as well as immune cell infiltration. These cells release inflammatory
mediators including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), among other cytokines
and chemokines which aggravate inflammation [31,42,43]. In addition, SF produce matrix-degrading
enzymes, also contributing to cartilage ECM degradation [28,29,44].
2.2. Rheumatoid Arthritis
RA is a severe and chronic systemic inflammatory autoimmune disease with unknown etiology
that mainly affects peripheral joints symmetrically, leading to progressive articular damage and joint
dysfunction. One of the hallmarks of RA is the persistent inflammatory infiltration of the synovial
sublining layer that contributes to generate a microenvironment in which stromal cells display a
hyper-activated phenotype, releasing several pro-inflammatory and tissue damaging mediators to
the joint space [45,46]. Although many of the underlying causes of RA are still unclear, systemic
and local immune dysregulation is considered to orchestrate its pathogenesis. In fact, this disease is
characterized by the production of autoantibodies such as anti-citrullinated protein antibody (ACPA)
and rheumatoid factor (RF), as well as by increased levels of e.g., TNF-α, IL-1β and IL-6 which are
recognised as central pro-inflammatory cytokines involved in chronic synovitis, osteoclast formation
and subsequent erosive joint damage. In this context, SF and synovial macrophages are recognized to
play a key role in driving RA pathology [8,47,48].
RASF characteristically exhibit an autonomous pathogenic phenotype that includes the capability
for hyperproliferation and migration, thus contributing to synovial hyperplasia and spreading RA
to unaffected joints [8,47,49]. Likewise, resident and monocyte-derived RA synovial macrophages
display a pro-inflammatory profile that has been linked to the pathological activity of RASF, and the
number of these cells in the synovium of affected joints has been shown to correlate with disease
activity and joint erosion [50–52]. Furthermore, it is generally accepted that endothelial cells under
synovial inflammatory conditions also contribute to chronic synovitis via angiogenesis and recruitment
of immune cells in RA [53].
3. Adiponectin
Adiponectin has previously been described as an anti-inflammatory adipokine mainly produced
and secreted by adipocytes [54]. The highly complex adiponectin molecules exist in different isoforms,
the globular form, the trimer (low molecular weight, LMW), the hexamer (middle molecular weight,
MMW) and the multimeric (high molecular weight, HMW) adiponectin. LMW, MMW and HMW
represent the main circulating forms of adiponectin while the monomer only seems to occur as an
intermediate in adipocytes [55].
Two receptors are mainly responsible for adiponectin signaling and the adiponectin isoforms
differ in their affinity to the respective receptors [56]. Other receptors such as T cadherin [57–60]
and PAQR3 [61] have also been discussed. Mainly anti-inflammatory effects at the systemic level
have been described for adiponectin in atherosclerosis but also for example in metabolic syndrome,
type 2 diabetes mellitus [56,62]. In contrast, adiponectin seems to have opposing effects on effector
cells of arthritis. Adiponectin was one of the first adipokines to be evaluated in the pathophysiology
of arthritis. Numerous studies found that cultured RASF respond to adiponectin by an increase
of pro-inflammatory factors including prostaglandin E2, IL-6, IL-8, MMPs-1, -13 [56,62]. However,
a stronger pro-inflammatory effect of the HMW isoforms has been described in contrast to LMW
adiponectin in these cells [56,62]. For some cell types, even opposing effects have been described for
specific adiponectin isoforms. For example, IL-6 secretion was induced by HMW adiponectin in human
monocytes (but had no such effect on lipopolysaccharide (LPS)-activated monocytes), while LMW
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adiponectin reduced IL-6 and increased IL-10 secretion in LPS-activated monocytes [63]. Other cell
types including chondrocytes, endothelial cells and lymphocytes showed a mainly pro-inflammatory
response to adiponectin [56,62]. Bone cells are affected as well by adiponectin in both OA and RA [15].
3.1. Adiponectin in OA
A recent meta-analysis showed that the systemic adiponectin concentration is higher in OA
patients compared to healthy controls [64] and a cross-sectional study described that serum adiponectin
and leptin were significantly and negatively associated with bone mineral density in OA of the knee in
contrast to resistin [65]. Furthermore, serum adiponectin levels were found to be significantly lower
in OA patients with metabolic syndrome when compared to OA without metabolic syndrome [66]
independent of the body mass index (BMI) [67]. In the context of OA, adiponectin was associated with
pain while resistin and visfatin were mainly associated with disability [68]. Interestingly, adiponectin
serum levels were shown to be negatively associated with serum MMP-13 in OA-related knee structural
abnormalities [69]. The synovial tissue and IPFP of OA patients with metabolic syndrome secreted less
adiponectin compared to those OA patients with metabolic syndrome, whereas leptin was increased in
OA patients with metabolic syndrome. Adipokine secretion by tissue reflected the systemic adipokine
levels observed in these patients [66]. In another study, evaluation of perisynovial and infrapatellar
adipose tissue depots revealed differences that were influenced by the BMI of the patient. Compared to
adipocytes in the IPFP and synovium of lean OA patients, obese patients showed significantly larger
adipocytes with increased synovial fibrosis, macrophage infiltration and toll-like receptor (TLR) 4 gene
expression in those patients while adiponectin expression in the synovium was lower in obese patients
compared to lean patients [70].
3.2. Adiponectin in RA
Systemic adiponectin levels have been described to be increased in chronic-inflammatory RA
and to be associated with disease activity and radiographic disease progression [56,62]. However, the
correlation with disease activity has been shown in some studies but not by others [62], a discrepancy
which still needs to be elucidated. Besides serum levels, synovial fluid concentrations of adiponectin
are increased in RA [17,71]. In RA patients, subcutaneous abdominal adipose tissue has been found
to secrete more adiponectin compared to subcutaneous abdominal adiposetissue from OA patients,
and the amount of adiponectin secreted from this tissue positively correlated with the 28-joint disease
activity score (DAS28) and disease duration [72].
Interestingly, RA patients with higher baseline adiponectin showed a more pronounced
improvement in inflammatory parameters after anti-TNF-α treatment [73]. Along this line, anti-IL-6
treatment significantly increased adiponectin and reduced chemerin levels in RA patients independently
of the disease treatment response [74].
In another recent study, adiponectin indirectly affected T follicular helper cells (Tfh), which did
not directly respond to adiponectin, by activating these cells via adiponectin stimulation of RASF,
mainly through IL-6. Liu et al. confirm that intraarticular injection of adiponectin increased synovial
inflammation with an increased frequency of Tfh in adiponectin-treated collagen-induced arthritis
(CIA) mice [75]. Targeting specific adiponectin isoforms using therapeutic antibodies specifically
against MMW/HMW adiponectin reduced the IL-6 and IL-8 induction in osteoblasts induced by those
isoforms [76]. In addition, Lee et al. showed that antibodies against MMW/HMW as well as against
MMW alone significantly ameliorated CIA in mice and that hence both these adiponectin isoforms
may contribute to progression of arthritis.
In another recent study, Qian and colleagues suggested a potential cardiovascular protective role
of IL-6 inhibition. Adiponectin and osteopontin (OPN) levels were increased and associated with each
other in RA serum [77], and RASF stimulation with adiponectin led to a dose-dependent increase in
OPN, which in turn caused increased monocyte (RAW264.7) migration. This increased migration could
be inhibited by blocking OPN. In vivo, OPN silencing reduced the amount of tartrate-resistant acid
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phosphatase positive osteoclasts and bone erosion in collagen-induced arthritis (CIA) mice. Therefore,
enhanced bone erosion in RA is suggested to be mediated by the induction of OPN in SF, thus increasing
the differentiation and recruitment of osteoclast precursors [77].
4. Leptin
Discovered in 1994 by Jeffrey Friedman et al. [78], leptin is the main adipokine secreted by
adipocytes, with a positive correlation with white adipose tissue mass [79,80]. It is a 16kDa
non-glycosylated protein encoded by the LEP (ob) gene, involved in appetite and obesity regulation
by the induction of anorexigenic factors and suppression of orexigenic neuropeptides. Leptin is
also implicated in basal metabolism, insulin secretion, bone mass, and reproduction among other
functions [78,80,81]. In addition to food intake- and eating-related hormones, leptin synthesis is
regulated by energy status, sex hormones and inflammatory mediators [82]. Leptin is mainly secreted
by adipose tissue but it is able to act peripherally and centrally, in the hypothalamus, by its release
to circulation [83]. Its biological effects are mediated by binding to the long form of leptin receptor
(LEPR), which belongs to the class I cytokine receptor superfamily [84].
Leptin is considered a pro-inflammatory adipokine involved in the “low-grade inflammatory
state” described in overweight and obese people [85]. In the immune system, leptin modulates
both innate and adaptive immunity: it activates proliferation and phagocytosis of monocytes and
macrophages, regulates cytotoxicity of natural killer (NK) cells, modulates neutrophils chemotaxis,
induces proliferation and inhibits memory T CD4 cells, suppresses type 2 T helper (Th2) phenotype
in favour of Th1, and modulates T regulatory (Treg) activity [80,86]. Most immune cells express
LEPR at their surface, which has also been described for chondrocytes, SF and osteoblasts [87,88].
In addition, pro-inflammatory cytokines induce leptin synthesis in acute infection and sepsis [89].
Involvement of leptin has been described in several physiological and pathophysiological conditions,
including vascular function, reproduction, immunity, and inflammation, as well as in rheumatic
diseases [80,90–94].
4.1. Leptin in OA
Increased leptin levels in serum and synovial fluid from OA patients have been described to be
involved in the physiopathology [95–99] and to be associated with pain and disease severity [99,100].
Single nucleotide polymorphisms (SNP) in the leptin gene and its receptor are linked to OA
development [101,102]. Moreover, DNA methylation in OA chondrocytes correlates with leptin
expression [103], which associates with the BMI [96]. Fan et al. reported different genes associated with
the leptin-induced OA phenotype in rats by microarray analysis, including genes related to MMPs,
inflammatory factors, growth factors, apoptosis, and osteogenesis [104].
In OA chondrocytes, leptin increased the production of the pro-inflammatory cytokine IL-1β,
as well as matrix-degrading enzymes, including MMP-1, -3, -9, and -13 [80,96,103], suggesting a
role in the inflammatory and degradative process that takes place during OA. Accordingly, leptin
also increased MMP-2, MMP-9, a disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS)-4 and ADAMTS-5, while it decreased fibroblast growth factor (FGF) and proteoglycan
synthesis in rats cartilage [105]. Moreover, leptin induced activation of type 2 nitric oxide synthase
(NOS2) in human and mouse chondrocytes, with the involvement of JAK2, PI3K, MEK1 and p38
MAPK signaling [106,107]. By contrast, Dumond et al. showed an anabolic effect of leptin in rat
chondrocytes [108]. Leptin also induced changes in chondrogenic progenitor cells causing senescence
by the inhibition of their migratory and chondrogenic potential, and the induction of their osteogenic
transformation [109].
A role of leptin in OA subchondral bone has also been described, showing an increased expression
which is related to high levels of alkaline phosphatase, osteocalcin, collagen type I and transforming
growth factor β (TGF-β) [110]. Finally, in relation to the inflammatory process, an increase of IL-6, IL-8
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and chemokine ligand 3 (CCL3) by leptin has been described in CD4+T cells from OA patients [111]. In
addition, Griffin et al. showed that leptin-impaired mice did not develop knee OA inflammation [112].
4.2. Leptin in RA
In RA, higher leptin serum levels are related to disease course and activity [113–116]. In addition
to the activity, leptin in serum and synovial fluid has also been linked to disease duration and joint
erosion [117].
Several authors have reported the involvement of leptin in joint inflammation by the modulation
of different inflammatory mediators. Correlation of leptin and IL-17 has been reported in plasma
from RA patients [118]. In addition, leptin induced IL-6 and IL-8 expression in SF from RA and OA
patients, where JAK2/STAT3, NF κB, and AP-1 signaling pathways were involved [119,120]. Leptin
also increased expression of the vascular cell adhesion molecule (VCAM)-1 in human and murine
chondrocytes, and is involved in leukocyte extravasation during RA and OA inflammatory processes.
JAK2, PI3K and MAPK intracellular signaling was shown to play a role in this context [87]. Moreover,
induction of MAPK signaling by leptin has also been described in RASF [120].
Correlation of leptin with RA pathology has been shown in animal models. Busso et al. reported
less severe arthritis in leptin-deficient mice, accompanied with a reduction in IL-1β and TNF-α
levels [121]. In addition, leptin injection in CIA mice increased Th17 response, exacerbating RA
severity and increasing synovial hyperplasia and joint damage [122]. Serum leptin concentrations also
correlated with body fat percentage in RA patients, working as an obesity marker [123]. Cardiovascular
risk is another factor associated to obesity and RA pathology. Accordingly, Batun et al. reported an
association between leptin and IL-6 concentrations with cardiovascular risk in these patients [124].
5. Resistin
Resistin is a dimeric cysteine-rich protein that circulates as a 108-amino acid homodimer in
human blood [125]. In humans, this adipokine is mainly produced by macrophages whereas in mice
it is primarily secreted by adipocytes [126]. In line with this, human resistin has been primarily
associated with inflammatory responses by promoting immune cell recruitment [127–129], whereas in
mice it has been mostly linked to the development of type 2 diabetes and obesity-mediated insulin
resistance [130,131]. However, conflicting results have been published regarding the modulatory role
of resistin on inflammatory responses, and whether this adipokine induces anti- or pro-inflammatory
effects on cells may depend on both the tissue and organ context and the disease studied [125].
Nevertheless, it is accepted that resistin is generally involved in inflammation and insulin resistance,
and subsequently in the development of different pathologies such as coronary artery disease,
atherosclerosis, type 2 diabetes, psoriasis and colorectal cancer [132–136]. In this sense, resistin has also
emerged as an adipokine implicated in the pathogenesis of OA and RA given its immunomodulatory
effects and the ability to enhance the activated phenotype of the effector cells involved in these
rheumatic diseases [98,129].
5.1. Resistin in OA
Numerous clinical studies have revealed that serum, plasma and synovial fluid resistin levels are
increased in OA patients compared with healthy subjects [98,137], suggesting that this adipokine may
act as a linker between the inflammatory process and the altered metabolism of joint tissues in the
pathogenesis of OA [138].
Resistin levels in the synovial fluid of OA joints have been found to exhibit a positive association
with symptomatic and radiographic severity as well as with articular cartilage damage. Moreover,
such levels of resistin have been reported to correlate with resistin released from cultured OA
cartilage [139–141]. Likewise, presence of inflammatory and catabolic factors in synovial fluid,
including IL-6, MMP-1, MMP-3 and collagen type II C-telopeptide fragments, also exhibited a positive
correlation with synovial fluid resistin levels [141,142]. Furthermore, these adipokine levels have been
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linked with pain and disability in OA patients with join effusion [143], although no association with
knee cartilage volume has been found [97,144].
Interestingly, in vitro studies have shown that resistin-stimulated human articular chondrocytes
display an upregulated expression of several pro-inflammatory mediators, including TNF-α, IL-6 and
IL-12 [145], and different cartilage catabolic enzymes and mediators, such as MMP1, MMP3, ADAMTS-4
and inducible cyclooxygenase (COX)-2, as well as a decreased production of some components of
cartilage ECM such as type II collagen and the proteoglycan aggrecan [146–148]. This ability of resistin
to promote catabolic over anabolic activity in OA chondrocytes has been confirmed in a recent study,
which further found that resistin modulates the expression of several microRNAs (miRNA) involved
in the pathogenesis of OA [149]. Accordingly, resistin stimulation of meniscal tissue explants from
OA patients resulted in a significant increase of sulfated glycosaminoglycan depletion [150] similar to
the dose-dependent loss of proteoglycan in murine cartilage [148]. Furthermore, resistin has also has
been found to induce the expression of monocyte chemoattractant protein-1 (MCP-1) by SF from OA
patients and to subsequently promote the monocyte migration and infiltration in synovium [151].
However, some inconsistent results have been published regarding the involvement of resistin
circulating levels in the pathophysiology of OA. On the one hand, serum levels of resistin have
demonstrated a positive correlation with bone marrow lesions and cartilage degradation, also
showing an association with different scoring systems for measuring severity, progression and
pain in OA [141,152]. Likewise, plasma resistin levels in OA were shown to be associated with
progression of radiographic knee [153]. On the other hand, other authors have not found any
significant relationship between serum resistin and OA radiographic severity, bone mineral density,
pain or cartilage damage [65,97,98,142,154]. Nevertheless, such serum levels exhibited a weak but
positive association with histological signs of synovial inflammation in OA patients [98]. Therefore,
while the potential pathogenic role of serum/plasma resistin levels needs to be further investigated,
there is evidence of the involvement of synovial fluid resistin in OA pathogenic mechanisms by
promoting pro-inflammatory responses and cartilage catabolic activity.
5.2. Resistin in RA
Resistin is present in blood plasma or serum, synovial fluid, and synovial tissue of RA patients.
Synovial stromal cells, including SF, and infiltrating immune cells, such as macrophages and B cells,
express resistin in joints affected by RA [155,156]. Higher resistin levels in synovial sublining layers
and also in synovial fluid from RA patients compared with OA have been described [17,155,157].
Regarding the potential pathological impact of synovial resistin levels in RA, it has been shown that
increased levels correlate with RA disease activity, joint damage [71], and inflammation intensity
defined by the intra-articular leukocytes count and IL-6 levels [128]. Conversely, in another study,
synovial fluid resistin did not show any significant relationship with inflammation degree based on
C-reactive protein (CRP) levels [155].
Besides, the available data concerning the circulating resistin levels in RA patients have also
generated conflicting conclusions. Although most studies describe no differences between serum or
plasma resistin levels in RA patients and controls [71,113,128,156,158], other authors have reported
higher resistin serum levels in RA when compared with healthy controls or with OA patients [155,159].
There is evidence that resistin serum levels in RA patients are positively correlated with inflammatory
markers, such as erythrocyte sedimentation rate (ESR) and CRP levels, as well as with the degree
of disease activity measured by DAS28 [113,155,160]. Another study also demonstrated a positive
correlation between circulating levels of this adipokine and TNF-α levels in blood from RA patients [161],
whereas no relationship with TNF-α, CRP levels, leukocytes counts, or with other pro-inflammatory
cytokines such as IL6, IL8, or MCP-1 was found by other authors [128,155].
Despite these controversial results regarding correlations between resistin levels in circulating
blood or in the joint with parameters of disease activity, there is a general agreement that this adipokine
is involved in the pathogenesis of RA. In fact, the intra-articular injection of recombinant resistin
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in healthy mice induced leukocyte infiltration and hyperplasia of the synovia, leading to a joint
inflammation similar to human arthritis [128]. Furthermore, in vitro stimulation of human synovial
fluid leukocytes and peripheral blood mononuclear cells (PBMC) with resistin induced the secretion of
IL-6, IL-1 and TNF-α by an NF κB-dependent pathway, providing a positive feedback circuit in PBMC
by stimulating also its own production [128]. Likewise, stimulatory effect of this adipokine on IL-12 and
TNF-α release by both murine and human macrophages was demonstrated to be mediated by the NF
κB pathway [127]. More recently, the ability of resistin to increase the production of pro-inflammatory
chemokines by SF has been shown [162]. Moreover, resistin has been considered as a key factor
triggering angiogenesis in RA affected joints through the upregulation of vascular endothelial growth
factor (VEGF) expression in endothelial progenitor cells and causing the homing of these cells to the
synovium [163].
The potential involvement of resistin in the RA inflammatory cascade is also sustained by the
rapid reduction of its serum levels observed in patients after anti-TNF-α therapy, showing a close
association with the inflammation marker CRP [164,165]. Accordingly, a downregulation of resistin
gene expression in CD4 Th lymphocytes and CD14 monocytes in RA patients responding to TNF-α
inhibitor therapy has recently been demonstrated, showing an increased expression in patients who
failed to respond to the therapy [166]. In addition, recent studies in a Chinese population have
demonstrated the association of SNP in the resistin gene with RA susceptibility as well as with its
clinicopathological characteristics [167,168].
6. Visfatin
Visfatin is also called pre-B-cell colony-enhancing factor (PBEF) for its ability to promote B cell
precursor differentiation (in synergy with IL-7) or nicotinamide phosphoribosyl-transferase (Nampt)
due to its enzymatic activity. However, whether altered systemic or local visfatin levels are associated
with changes in the nicotinamide adenine dinucleotide content due to the Nampt activity of visfatin is
not well studied. It is produced by adipose tissue but also other tissues such as the liver, bone marrow,
and muscle tissue. Visfatin can be induced by inflammatory factors such as TNF-α, IL-1β, IL-6, LPS
and chemokines as well as itself [15,56,62].
Hypoxia as found in inflamed joints may also play a role since hypoxia-inducible factor 2alpha
(HIF-2α) directly induced visfatin in chondrocytes [169]. In turn, visfatin is able to induce a
pro-inflammatory response in a large number of different cell types [115]. In contrast to adiponectin,
visfatin is primarily pro-inflammatory. These pro-inflammatory responses have also been described in
the effector cells of joints affected by arthritis, for example in SF, lymphocytes, monocytes, chondrocytes
or bone cells [15,170]. However, although visfatin is increased in both OA and RA, compared to healthy
controls, the levels differ between these two diseases. Likewise, the potential to respond to visfatin is
similar in OA- and RA-derived cells but the responses, although pro-inflammatory in both cases, differ
in strength between RA and OA [11,29].
Visfatin is also associated with insulin-like effects: It regulates insulin secretion, insulin receptor
phosphorylation and insulin-related intracellular signaling [171,172] but the work by Fukuhara et al.
(2007) that originally reported visfatin to interact with the insulin receptor was retracted. Therefore, as
of now, visfatin does not have a known receptor and several studies showed that its effects are at least
in part due to its Nampt activity [173].
Another mechanism includes its influence on insulin-like growth factor-1 (IGF-1) function.
Amongst others, IGF-1 is involved in cartilage synthesis and repair by stimulating proteoglycan and
collagen type II synthesis. Visfatin has been shown to inhibit these IGF-1 functions, independently of
IGF-1 receptor activation [174]. Altered levels of miRNAs may be another means how visfatin mediates
its effects as a range of miRNAs were either increased (miR-155, -34a, -181a) or decreased (miR-140,
-146a) in OA chondrocytes by visfatin [149].
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6.1. Visfatin in OA
Systemic visfatin levels are increased in OA patients compared to healthy controls [175,176] but
serum levels are lower compared to chronic-inflammatory diseases such as RA. However, OASF
respond to visfatin even at low concentrations with increased secretion of pro-inflammatory factors
such as IL-8, MCP-1 and other chemokines [170]. Visfatin also induced IL-6 and TNF-α in SF from OA
patients, which was mediated by the repression of the miRNA miR-199a-5p via different signaling
pathways including ERK, p38, and JNK [177].
A cell culture study on OA suggests a catabolic effect of visfatin because treatment of human
chondrocytes with IL-1β resulted in an increased synthesis of the matrix-degrading enzymes MMP-3,
MMP-13, ADAMTS-4 and ADAMTS-5 and a decreased synthesis of the extracellular matrix component
aggrecan [178]. In line with these effects, visfatin significantly reduced viability, induced apoptosis as
well as MMP-1 and MMP-13 secretion in OA chondrocytes [149].
6.2. Visfatin in RA
In RA patients, systemic visfatin levels have been shown to be increased in comparison to OA
patients and healthy donors and a positive correlation between visfatin and RA disease activity and
inflammatory parameters such as CRP has been described [56,62,115]. According to a recent study,
visfatin expression is associated with reduced atherosclerotic risk in RA patients [179].
Animal models have also shown a potential role of visfatin in RA. In a murine CIA model,
visfatin-deficient mice displayed reduced bone destruction, inflammation and disease progression [180].
In this study from Li and coworkers, visfatin has been shown to be required for osteoclastogenesis. In
another study, use of the selective inhibitor APO866, which inhibits the Nampt activity of visfatin,
reduced the severity of arthritis in a CIA mouse model and the production of pro-inflammatory
cytokines in the affected mouse joints [173].
7. Other Adipokines in OA and RA
7.1. Progranulin
Human progranulin (PGRN, also known as granulin/epithelin precursor) is a glycoprotein of
approximately 75–80 kDa which is composed of seven granulin/epithelin repeats (granulins) that
can undergo enzymic proteolysis into small homologous subunits. Both full-length protein and its
constituent granulin peptides are biologically active although often with anti- and pro-inflammatory
actions, respectively [181]. PGRN was originally described as an autocrine growth factor that stimulates
chondrocyte differentiation and proliferation [182], as well as endochondral ossification [183,184].
Moreover, PGRN has also been identified as an adipokine with anti-inflammatory properties mainly
mediated by its competitive binding to TNF-α receptors (TNFR1 and TNFR2), which disturbs
TNF-α-induced responses [80,185].
Multiple studies have reported significantly increased PGRN levels in cartilage, synovial fluid,
as well as in serum from OA and RA patients compared with healthy donors, with higher levels in
RA [186–188]. Regarding the potential pathogenic role of PGRN, a correlation between circulating
PGRN levels and disease activity has been shown in RA patients [189]. In this sense, a recent study in
Hispanic RA patients found a correlation between changes in serum PGRN levels and RA progression
scores over time, although serum concentrations of PGRN did not predict the clinical response to
TNF-α-antagonist therapy [190]. The presence of antibodies against PGRN (PGRN-abs) has been
detected in sera from patients with different rheumatic diseases, including RA, showing neutralizing
effects on PGRN plasma levels [191]. More recently, it has been proved that PGRN-abs positive RA
patients exhibit higher disease activity compared to negative patients, and that a pattern of increased
rates of PGRN-abs is observed in the serum of RA patients with poorer outcome [192].
PGRN is secreted by a broad spectrum of cells, including adipocytes, macrophages and
chondrocytes [193], and an increased expression of this adipokine has been found during chondrocytes
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differentiation in vitro, in the IPFP from OA patients [186], as well as in cells infiltrating the sublining
layer of RA synovium [187]. Hence, the increased expression of PGRN at local sites of inflammation is
suggested to be linked to its ability to initiate immune activation by recruiting fibroblasts, macrophages
and neutrophils at the site of inflammation [194]. However, on the other hand, it is now generally
accepted that PGRN is also an important mediator in the maintenance of cartilage integrity. This
adipokine is able to inhibit the ADAMTS-7/-12 mediated degradation of cartilage oligomeric matrix
protein by interfering with direct interactions between these catabolic enzymes and their substrate, as
well as by inhibiting the TNF-α-induced expression of both ADAMTS in human chondrocytes [195].
Furthermore, treatment with PGRN has been demonstrated to inhibit proteoglycan loss and the
expression of catabolic inflammatory biomarkers induced by TNF-α in cultured human cartilage [196].
In fact, PGRN has been described to trigger anabolic pathways in human cartilage and primary
chondrocytes by binding to TNFR2, and to inhibit the IL-1β and LPS induced catabolic metabolism in
chondrocytes by blocking TNFR1 [193,197]. In addition, a negative modulation of Wnt/catenin signaling
by PGRN has been shown, with the consequent reduction of osteophyte formation and cartilage
degeneration [198,199]. PGRN has also demonstrated a protective effect on osteoblast differentiation
under an inflammatory milieu by blocking the inhibitory effects of TNF-α on this process [200]. Despite
its chondro- and osteoprotective potential, increased PGRN levels as observed in both OA and RA
patients are obviously not sufficient to compensate for the catabolic effect of other mediators [181].
Interestingly, an association between serum PGRN levels, functional impairment and disease
activity has been found in RA patients [189], in which the balance between PGRN and TNF-α
also showed a direct correlation with disease progression [186]. In this regard, different
animal models of both OA and RA have demonstrated that loss of PGRN expression results
in hyper-susceptibility to develop more severe disease phenotypes [185,196]. Along this line, a
recent study has showed that the miR-29b-3p promotes disease development and chondrocyte
apoptosis in an OA rat model by modulating PGRN expression [201]. Accordingly, administration
of recombinant PGRN or the PGRN-derived atsttrin in OA and RA animal models protected against
the development of such rheumatic disorders by, at least in part, inhibiting the TNF-α/TNFR
signaling in vivo [183,185,196,202–204]. Moreover, atsttrin-transduced mesenchymal stem cells have
demonstrated to inhibit cartilage degeneration in an OA murine model after intra-articular injection,
and to reduce the TNF-α induced expression of pro-inflammatory molecules by human primary
chondrocytes [197].
Other studies in animal arthritis models have shown that PGRN also exerts its immunosuppressive
effect by promoting the differentiation, proliferation and recruitment of Treg cells under inflammatory
conditions, as well as by inducing IL-10 production [185,205,206]. In this regard, more recently, a study
described higher levels of PGRN and human B regulatory cells in RA patients, but without finding a
correlation between them [189].
7.2. Chemerin
Chemerin is expressed as a 163 amino acid residues-long adipokine that becomes activated after
hydrolization by cysteine or serine proteases [207]. The precursor is composed of a hydrophobic signal
peptide sequence, a cystatin fold-containing domain, and a labile C terminus. Removal of the signal
sequence results in a 143-amino acid secreted preform (prochemerin or chem163S) with low biological
activity. Different cleaved isoforms of chemerin have been described depending on the location.
Cleavage of the last four amino acids from chem163S rise to chem158K, and removal of the C-terminal
lysine from chem158K, results in chem157S, the most active chemerin form. In addition, chem156F, a
chemerin C-terminal peptide, is functionally active in vitro [208,209]. Anti-inflammatory properties
have been described by mouse chem156S, homologous to human chem157S, on macrophage [210] and
in a LPS-induced acute lung injury model [211]. Chemerin plays an important role in the development
of coronary atherosclerosis, metabolic syndrome and other diseases [212]. It is also involved in innate
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and adaptative immunity working as a chemoattractant for NK cells, macrophages and dendritic
cells [213,214].
In relation to rheumatic diseases, chondrocytes and SF from RA and OA patients express both
chemerin and its receptor chemokine-like receptor 1 (CMKLR1) [208,215,216]. In addition, Zhao et al.
described the presence of chem156F in synovial fluid samples from patients with OA and RA [208].
Chemerin induced expression of inflammatory and degradative mediators in these cells, including IL-6,
CCL2, and MMP-3 in RASF, CCL2, and TLR4 in SF from RA and OA patients, and IL-1β in chondrocytes.
In addition, chemerin stimulated SF motility and leukocyte migration to the joint [209,216–218].
Cleaved isoforms of chemerin have been described in synovial fluid samples from RA and
OA patients [208]. Ma et al. reported higher levels of chemerin in the synovial fluid and synovial
membrane of knee OA patients compared to controls. Chemerin levels also correlated with serum
levels of CRP and OA severity [219,220]. Similar results were obtained in patients with OA of the
temporomandibular joint, with higher levels this adipokine in synovial fluid and correlation with OA
severity and pain [221]. A recent study in a rat OA model showed that chemerin aggravated the disease
by inducing activation of Akt/ERK signaling, and by increasing the expression of MMP-1, MMP-3, and
MMP-13 in IL-1β activated chondrocytes as well as by decreasing their proliferative capability [222].
In RA, chemerin plasma levels correlated with disease activity and BMI, which is a risk factor
in the pathology, arising as a biomarker of meta-inflammation [223]. In addition, the IL-6 inhibitor
tocilizumab has an anti-inflammatory and antithrombotic/fibrinolytic role and is able to decrease serum
chemerin levels in RA patients [74].
7.3. Lipocalin-2
LCN2 is an adipokine produced in joint tissues in response to both mechanical loading and
inflammatory mediators [218,224,225]. Specifically, LCN2 expression in chondrocytes is induced
by IL-1β, LPS, dexamethasone, adipokines (leptin and adiponectin) [218,226,227] and by osteoblast
conditioned medium [228], establishing also a feedback regulatory loop with the catabolic factor
nitric oxide [229]. In osteoblasts, the inflammatory molecules TNF-α and IL-17 [230] can induce
an upregulated expression of this adipokine, which is able to shift the balance between pro- and
anti-osteoclastogenic factors toward a more catabolic metabolism [227,231]. In this sense, a recent
study confirmed the catabolic effects of LCN2 in osteoblasts and chondrocytes from OA osteochondral
junctions, also showing that osteoblasts induced its expression in a paracrine manner [228].
Although there are data pointing to the involvement of LCN2 in the joint pathophysiology of
OA and RA, further studies are needed to elucidate its role in human development of such rheumatic
diseases. LCN2 concentration was found to be elevated in synovial fluid of patients with OA and
RA, with higher levels in RA [224,225,232]. In OA patients, elevated LCN2 levels in synovial fluid
and cartilage have been linked to cartilage matrix destruction given its ability to reduce chondrocyte
proliferation and to form a covalent complex with MMP-9 that blocks its auto-degradation [224,225,227].
However, studies in mice have shown that LCN2 overexpression in mouse cartilage is not enough
to induce OA pathogenesis, and that its absence has no consequences in the induction of cartilage
destruction in Lcn2-knockout mice [233]. Regarding RA patients, serum levels of this adipokine have
been reported to be an indicator for structural damage in early-stage RA, but not for monitoring disease
activity [234]. Likewise, induced LCN2 expression in neutrophils by the granulocyte macrophage
colony-stimulating factor has been linked with synovial cell proliferation and inflammatory cell
infiltration in RA synovium [225]. Of note, glucocorticoids (normally used to treat OA and RA)
have been described to induce the expression of LCN2 by mouse chondrocytes in synergy with IL-1,
suggesting that this adipokine may mediate some of the degradative effects on cartilage described
after prolonged treatment with such drugs [235].
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7.4. Vaspin
The adipokine vaspin belongs to a serine protease inhibitor family known to be associated with
insulin resistance as well as metabolic syndrome [236]. Also, a link between vaspin and artherosclerosis
and cardiovascular disease has been suggested [237]. Vaspin is expressed in several tissues including
subcutaneous adipose tissue, skin, stomach and skeletal muscle [238]. In OA patients undergoing joint
surgery, it was detected in cartilage, synovium and osteophytes [239]. In the same study, it was found
that vaspin serum levels exceeded synovial fluid levels in paired samples.
Studies investigating potential inflammation-related effects of this adipokine are not always in
agreement, which may be due to differences between the studied diseases including RA, OA, PsA,
juvenile idiopathic arthritis and ankylosing spondylitis. For example, vaspin has been shown to be
involved in skeletal muscle inflammation [238] and its serum levels were associated with inflammation
in RA [165,240] and with the development of clinically manifest RA after follow up (in contrast to other
adipokines) [241]. In an animal study, Transgenic mice overexpressing vaspin showed specific changes
in metabolism- and inflammation-related markers: Glucose tolerance was improved, the mice were
resistant to high-fat diet induced obesity and had lower systemic IL-6 levels [242]. Cellular effects for
this adipokine have also been observed, mainly in the context of metabolism. For example, vaspin has
been described to modulate adipocyte differentiation and glucose homeostasis [243]. In the context of
human coronary atheromatous plaques, the pro-inflammatory phenotype of human macrophages was
suppressed by vaspin [244].
Systemically, serum levels of vaspin were found to be higher in psoriatic arthritis (PsA) patients
compared to healthy controls [245], whereas levels were lower in OA patients compared to healthy
controls [239]. In synovial fluid, vaspin levels were significantly higher in RA compared to OA patients
with a tendency to correlate with DAS28 in the RA group [246]. However, an association of serum vaspin
with the inflammation markers CRP or ESR could not be identified in this study. Interestingly, inhibiting
inflammation in RA patients by short-term treatment with high-dose glucocorticoids increased vaspin
levels [165], suggesting an association with inflammation albeit probably not in a causal manner. On
the other hand, in juvenile idiopathic arthritis, vaspin level did not differ significantly compared
to healthy controls [247] and there was no association between disease activity and vaspin serum
levels [248]. Interestingly, in patients with ankylosing spondylitis low vaspin levels were related to
endothelial dysfunction [249].
However, vaspin also affected bone cells and chondrocytes in vitro: Human osteoblasts were
protected from apoptosis [250] and osteoclastogenesis was inhibited in the pre-osteoblast cell
line MC3T3-E1 [251], the murine macrophage cell line RAW264.7 and bone marrow-derived cells.
Furthermore, in the RAW264.7 cells, vaspin reduced the RANKL-induced expression of cathepsin K
and MMP-9 [252]. Vaspin was also able to inhibit the IL-1β [253] as well as the leptin [254] induced
production of catabolic and pro-inflammatory mediators in murine or rat chondrocytes, respectively.
These are potential pathomechanisms by which vaspin might contribute to certain arthritic diseases.
7.5. Omentin-1
Omentin was discovered as a secretory glycoprotein binding to galactofuranosyl residues on
microorganisms as well as a lactoferrin-binding protein. Its role in omental adipose tissue, hence
its name, was described in patients with Crohn’s disease. But omentin is also highly abundant in
plasma of healthy donors [255]. Most studies point towards omentin as an anti-inflammatory molecule.
For example, this adipokine showed anti-inflammatory and anti-atherogenic properties in obese
individuals [256] and a negative association with inflammatory bowel disease and metabolic syndrome
has been described [255,257,258].
As far as rheumatic diseases are concerned, the role of omentin is rather inconclusive. In serum,
omentin was found to be higher in juvenile idiopathic arthritis (JIA) [247] and PsA [248] patients
compared to healthy controls. Furthermore, serum levels were higher in JIA patients with active
synovitis in comparison to those without active joints [247]. On the other hand, in synovial fluid,
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omentin levels were found to be lower in chronic-inflammatory RA compared to OA [246]. For RA,
an association of omentin with the inflammation marker CRP at baseline has been reported [241].
The level of omentin-1 in synovial fluid of OA patients negatively correlated with self-reported pain
and physical disability (as measured by the WOMAC score) in OA patients [259], intended to reflect
symptomatic severity in OA. This is in line with the observed inverse correlation between synovial
fluid omentin-1 and radiographic severity as assessed by the Kellgren-Lawrence grading [260].
In synovial tissue, omentin was expressed in the synovial lining layer as well as perivascularly ;
however, no difference was detectable between RA and OA tissues [261]. In RA, omentin concentrations
were inversely associated with MMP-3 levels and influenced by different factors such as disease activity
but showed no association with endothelial activation and atherosclerosis in this study [262].
The knowledge regarding specific effects of omentin on different cell types in synovial tissue
and systemic inflammation is very limited. For example, the response of RA and OA SF towards
omentin was very low [67], suggesting that other effector cells may respond to omentin. Interestingly,
Calvet et al. observed a non-significant trend between adiponectin and omentin levels was observed
when other adipokines were included in the multivariate linear statistical model using the partial
correlation coefficient (PCC) for interpretation [143].
7.6. Nesfatin
Nesfatin-1 (nesfastin) is an N-terminal 82-amino-acid peptide nucleobindin-2-derived adipokine,
involved in satiety induction and energy homeostasis. Nesfatin was first described as an anorexigenic
molecule secreted by the hypothalamus [263] but it is also secreted by subcutaneous adipose tissue,
gastric mucosa, pancreatic cells, and testes [264].
Higher nesfatin levels have been detected in serum from OA patients compared to controls [265,266].
Moreover, nesfatin serum and synovial fluid concentrations have been associated with radiographic
severity in OA [266], where its levels also correlated with CRP and IL-18 in serum and synovial fluid,
respectively. In addition, nesfatin has been detected in human and murine chondrocytes, inducing
pro-inflammatory mediators such as COX-2, IL-8, IL-6, and CCL3 in chondrocytes from OA patients [95].
In contrast, recent studies also described this adipokine as an anti-inflammatory molecule [264,267]
able to reduce cardiovascular risk [268,269].
In relation to RA, a study demonstrated a positive association between nesfastin and rheumatoid
factor in RA patients. In addition, nesfatin concentration correlated with MMP-2, and reduced
atherosclerosis in these patients [179].
Akour et al.also described nesfatin activation by the endocrine growth factor FGF21 [270], which
has been described as a new adipokine related to BMI in RA patients [271]. Association between
FGF21 and rheumatic diseases would be of interest as FGF21 ameliorates CIA by regulating oxidative
stress and inflammatory response [272,273]. In addition, FGF21, also inhibits macrophage-mediated
inflammation [274] and down-regulates Th17-IL17 axis in CIA mice [275]. In relation to OA, FGF21
concentration in serum and synovial fluid is associated with radiographic knee bone loss [276].
8. Concluding Remarks
Common consequences of two of the most prevalent rheumatic diseases, OA and RA, are severe
long-term pain and loss of locomotor function, with the subsequent negative impact on health care
burden and social system. In order to reduce such socio-economic costs it is necessary to progress in
the diagnosis, treatment and in the identification of disease severity biomarkers which requires a more
detailed understanding of the diverse factors involved in the initiation and progression of these joint
diseases. While the complex etiology of OA and RA are still unclear, and despite the differences between
the pathophysiology underlying these joint degenerative diseases, it is now generally accepted that
they share similar inflammatory pathways that contribute to synovitis and the loss of balance between
cartilage and subchondral bone, leading to the progressive destruction of affected joints [6,8,31,45].
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This review summarized the more relevant clinical and experimental lines of evidence for
the connection between classic and novel adipokines and the cellular and molecular pathogenic
characteristics of two of the most common rheumatic diseases, OA and RA. However, given the
pleiotropic action of these molecules and their immunomodulatory effects at both local and systemic
levels, the study of their role in the pathogenesis and progression of rheumatic diseases is very complex
and has generated conflicting results. In this sense, both pro- and anti-inflammatory effects have
been associated with the same adipokine, evidencing that their biological actions depend on the
inflammatory context and the disease conditions (Figure 1). Moreover, the correlation between the
levels of a particular adipokine in the synovial fluid and the activity/progression of a rheumatic disease
may disappear when circulating levels are considered. In fact, when it has been studied whether there
is an relationship between synovial and serum levels of adipokines with the development of arthritis
in autoantibody-positive individuals at risk of RA, only a significant association between serum levels
of vaspin and the disease development was found [241], thus evidencing the complexity of assessing
their potential as diagnostic biomarkers.
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Figure 1. Graphical schematic representation of the role of classic and novel adipokines in two rheumatic
diseases: osteoarthritis (OA) and rheumatoid arthritis (RA). A variety of adipokines produced by
adipose tissue (blue line of arrows) as well as by chondrocytes, osteoclasts, osteoblasts, synoviocytes
and inflammatory cells (blue dashed line and blue line formed by arrows), contribute to multiple
pathological mechanisms (solid arrows) involved in the development of OA and RA. Although there are
differences between the pathog nesis of OA and RA, common mechanisms have also b en identified that
affect cartilage extracellular matrix (ECM) in egrity, dysregulation of bone metabolism, the pathogenic
phenotype of synovial fibroblasts and macrophages, modula ion of the immune system nd synovial
angiogenesis. D pending on the context, both pro- and anti-inflammatory ffects have been associated
with so e dipokines, such as visf tin and resistin. Adipokines with a dominant pro-i flammatory
role in arthritis are shown with a light red background, whereas those in w ich an anti-inflammatory
action predominates are shown with a green background.
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All in all, it is worthy to note that the contribution of adipokines to the pathogenesis of rheumatic
diseases should be understood as cross-talking networks that coordinate with other molecular mediators
to orchestrate the activity of effector cells involved in OA and RA. In this regard, activated resident
cells in joints affected by these rheumatic diseases are probably the main contributors to the increased
levels of adipokines detected in synovium, consequently suggesting that antagonizing local specific
adipokines may be a viable option for the development of new therapeutic strategies. However, further
research is needed to determine the exact contribution of the adipokine network to rheumatic disorders,
which would also help to identify which adipokine could be considered a potential diagnostic and/or
prognostic biomarker for OA and RA.
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Abbreviations
OA Osteoarthritis
RA Rheumatoid arthritis
ROS Reactive oxygen species
SF Synovial fibroblasts
IPFP Infrapatellar fat pad
ECM Extracellular matrix
MMPs Matrix metalloproteinases
IL-1β Interleukin-1β
TNF-α Tumor necrosis factor-α
ACPA Anti-citrullinated protein
RF Rheumatoid factor
LMW Low molecular weight
HMW High molecular weight
LPS Lipopolysaccharide
TLR Toll-like receptor
DAS-28 28-joint disease activity score
OPN Osteopontin
CIA Collagen-induced arthritis
Tfh T follicular helper cells
LEPR Leptin receptor
NK Natur killer
Th2 Type 2 T helper cells
Treg T regulatory cells
SNP Single nucleotide polymorphism
ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs
NOS2 Type 2 nitric oxide synthase
TGF-β Transforming growth factor β
CCL3 Chemokine ligand 3
VCAM-1 Vascular cell adhesion molecule-1
COX-2 Catabolic cyclooxygenase-2
miRNA MicroRNA
MCP-1 Monocyte chemoattractant protein-1
CPR C-reactive protein
PBMC Peripheral blood mononuclear cells
VEGF Vascular endothelial growth factor
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PBEF Pre-B-cell colony-enhancing factor
Nampt Nicotinamide phosphoribosyl-transferase
HIF-2α Hypoxia-inducible factor 2alpha
IGF-1 Insulin-like growth factor-1
PGRN Progranulin
TNFR TNF-α receptors
PGRN-abs Antibodies against Progranulin
CMKLR1 Chemokine-like receptor 1
LCN2 Lipocalin-2
PsA Psoriatic arthritis
JIA Juvenile idiopathic arthritis
WOMAC Western Ontario and McMaster Universities Arthritis Index
PCC Partial correlation coefficient
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